

Instructions:

		• Please complete and fax this prior authorization form along with all applicable documentation required directly to					
Neighborhood Health Plan of Rhode Island at 1-866-423-0945 for review.							
• Limited Specialty Pharmacy Network applies. Please fax prescription to one of the following 3 specialty pharmacies:							
1. Care New England Specialty Pharmacy Phone: 855-981-1908 Fax: 401-889-5050							
2.CVS Specialty PharmacyPhone: 800-237-2767Fax: 800-323-2445							
3. Lifespan Specialty Pharmacy Phone: 401-444-9909 Fax: 401-4							
MEMBER INFORMATION							
Member's Name:	Member's ID Number:			Member's DOB:			
PRESCRIPTION INFORMATION							
Medication Name/Strength	Directions			Quantity	Refills		
					1		
PRESCRIBER INFORMATION							
Prescriber's Name: Specialty:							
Address:							
City:State		Zip Code:					
City:State	F	ax #:		_			
Office Contact Name:							
Prescriber's Signature Required: Date:							
Prescriber's Signature Required: Date: Dat							
Treatment naïve							
Turneture and States	□ Retreatment (prior treatment failure with another HCV agent)						
Treatment Status:	*If request is for Vosevi, no further information is required.						
	Currently on therapy: Provide Start Date:						
Provide previous Hepatitis C drug	Drug(s):Date(s):						
therapy (If applicable):	□ Side effect □ Inadequate response □ Other:						
Hepatitis C Genotype:	□ 1 □ 2 □ 3 □ 4 □ Other:						
Hepatic Fibrosis Stage:	□ Stage 0 □ Stage 1 □ Stage 2 □ Stage 3 □ Stage 4						
Test used to determine disease stage					antest secure		
(Check all that apply):	□ AST to Platelet Ratio Index (APRI) □ Fibroscan score □ Fibrotest score □ Imaging study □ Liver biopsy indicating METAVIR score						
Documentation must be submitted							
with PA request	• Other, please specify:						
Is cirrhosis present?	□ Yes - If yes, □ Compensated Cirrhosis <u>OR</u> □ Decompensated Cirrhosis						
1	□ No	1		1			
If requested, does the prescriber							
agree to submit post treatment viral	□ Yes □ No						
load data?							
Rationale as to why member is							
unable to use preferred HCV agents							
Mavyret and/or Vosevi. Clinical							
documentation must be provided.							